X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (50762) 50762
Newsletter (1120) 1120
Newspaper Article (212) 212
Dissertation (186) 186
Book Chapter (115) 115
Conference Proceeding (61) 61
Magazine Article (45) 45
Publication (33) 33
Government Document (31) 31
Book / eBook (13) 13
Streaming Video (13) 13
Transcript (10) 10
Web Resource (8) 8
Book Review (6) 6
Reference (4) 4
Paper (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32059) 32059
paclitaxel (31829) 31829
female (20561) 20561
oncology (18784) 18784
chemotherapy (13946) 13946
middle aged (12647) 12647
cancer (12558) 12558
paclitaxel - administration & dosage (12454) 12454
aged (11136) 11136
male (10710) 10710
animals (9267) 9267
antineoplastic combined chemotherapy protocols - therapeutic use (9172) 9172
adult (8820) 8820
paclitaxel - pharmacology (7207) 7207
treatment outcome (7084) 7084
pharmacology & pharmacy (6560) 6560
cisplatin (5674) 5674
cell line, tumor (5584) 5584
paclitaxel - therapeutic use (5178) 5178
mice (4973) 4973
breast neoplasms - drug therapy (4934) 4934
breast cancer (4842) 4842
taxol (4833) 4833
research (4532) 4532
carboplatin (4459) 4459
care and treatment (4426) 4426
therapy (4199) 4199
apoptosis (4187) 4187
docetaxel (4142) 4142
paclitaxel - adverse effects (3851) 3851
lung neoplasms - drug therapy (3838) 3838
nanoparticles (3833) 3833
ovarian neoplasms - drug therapy (3793) 3793
carcinoma (3704) 3704
ovarian cancer (3654) 3654
analysis (3635) 3635
trial (3589) 3589
antineoplastic combined chemotherapy protocols - adverse effects (3585) 3585
tumors (3365) 3365
carboplatin - administration & dosage (3359) 3359
neoplasm staging (3359) 3359
doxorubicin (3332) 3332
drug delivery systems (3302) 3302
survival (3188) 3188
aged, 80 and over (3173) 3173
antineoplastic agents - therapeutic use (3129) 3129
expression (3028) 3028
antineoplastic agents, phytogenic - administration & dosage (2983) 2983
drug administration schedule (2983) 2983
cisplatin - administration & dosage (2981) 2981
antineoplastic agents (2957) 2957
antineoplastic agents, phytogenic - pharmacology (2946) 2946
breast neoplasms - pathology (2941) 2941
antineoplastic agents - pharmacology (2925) 2925
drugs (2910) 2910
carcinoma, non-small-cell lung - drug therapy (2903) 2903
disease-free survival (2854) 2854
metastasis (2843) 2843
prognosis (2758) 2758
dose-response relationship, drug (2711) 2711
in-vitro (2693) 2693
antimitotic agents (2676) 2676
antineoplastic agents, phytogenic - therapeutic use (2629) 2629
apoptosis - drug effects (2553) 2553
gemcitabine (2529) 2529
drug therapy (2526) 2526
time factors (2509) 2509
combination (2475) 2475
health aspects (2412) 2412
biochemistry & molecular biology (2384) 2384
retrospective studies (2379) 2379
medicine & public health (2378) 2378
cancer therapies (2355) 2355
cardiac & cardiovascular systems (2315) 2315
survival rate (2313) 2313
obstetrics & gynecology (2309) 2309
antineoplastic agents - administration & dosage (2209) 2209
paclitaxel - analogs & derivatives (2201) 2201
breast-cancer (2182) 2182
ovarian neoplasms - pathology (2159) 2159
paclitaxel - chemistry (2158) 2158
deoxycytidine - analogs & derivatives (2155) 2155
combined modality therapy (2149) 2149
taxoids (2142) 2142
surgery (2141) 2141
survival analysis (2138) 2138
antineoplastic combined chemotherapy protocols - administration & dosage (2132) 2132
cells (2102) 2102
drug resistance, neoplasm (2078) 2078
chemistry, multidisciplinary (2046) 2046
lung neoplasms - pathology (2033) 2033
clinical trials (1998) 1998
cell biology (1996) 1996
cell survival - drug effects (1994) 1994
toxicity (1993) 1993
follow-up studies (1962) 1962
phase-ii (1949) 1949
neoplasms - drug therapy (1903) 1903
bevacizumab (1897) 1897
phase-ii trial (1880) 1880
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (50265) 50265
Japanese (1206) 1206
Chinese (591) 591
French (399) 399
German (317) 317
Korean (164) 164
Spanish (134) 134
Russian (94) 94
Portuguese (80) 80
Italian (67) 67
Polish (43) 43
Hungarian (28) 28
Czech (25) 25
Dutch (15) 15
Turkish (15) 15
Danish (5) 5
Hebrew (5) 5
Swedish (5) 5
Lithuanian (4) 4
Finnish (3) 3
Slovak (3) 3
Croatian (2) 2
Slovenian (2) 2
Bulgarian (1) 1
Norwegian (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Heart Association, ISSN 2047-9980, 2018, Volume 7, Issue 24, p. e011245
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 02/2013, Volume 166, Issue 1, pp. 66 - 74
The performance and safety of current antineoplastic agents, particularly water-insoluble drugs, are still far from satisfactory. For example, the currently... 
N-(2-hydroxypropyl)methacrylamide (HPMA) | Biodegradable multiblock copolymer | Paclitaxel | Ovarian cancer | MOLECULAR-WEIGHT | N-(2-hydroxypropyl)methactylamide (HPMA) | CANCER | CHEMISTRY, MULTIDISCIPLINARY | OVARIAN-CARCINOMA | CHEMOTHERAPY | TARGETING DELIVERY | N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS | BODY DISTRIBUTION | CONJUGATE | PHARMACOLOGY & PHARMACY | IN-VIVO EVALUATION | CREMOPHOR EL | Molecular Weight | Nanoparticles - chemistry | Paclitaxel - chemical synthesis | Biocompatible Materials - chemistry | Humans | Ovarian Neoplasms - pathology | Acrylic Resins - chemical synthesis | Paclitaxel - pharmacokinetics | Drug Carriers - chemistry | Biocompatible Materials - chemical synthesis | Tissue Distribution | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Acrylic Resins - pharmacokinetics | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Ovarian Neoplasms - drug therapy | Cell Survival - drug effects | Paclitaxel - analogs & derivatives | Drug Carriers - chemical synthesis | Acrylic Resins - chemistry | Paclitaxel - therapeutic use | Acrylamides - chemistry | Xenograft Model Antitumor Assays | Acrylic Resins - therapeutic use | Animals | Mice, Nude | Cell Line, Tumor | Mice | Acrylamides - chemical synthesis | Drugs | Drug delivery systems | Dosage and administration | Vehicles | Index Medicus | Ascites | paclitaxel | biodegradable multiblock copolymer | ovarian cancer
Journal Article
Journal of clinical pharmacology, ISSN 0091-2700, 2014, Volume 54, Issue 10, pp. 1097 - 1107
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 07/2015, Volume 9, pp. 3767 - 3777
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 3/2008, Volume 108, Issue 2, pp. 241 - 250
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1744-7666, 2006, Volume 7, Issue 8, pp. 1041 - 1053
Journal Article
ACS Nano, ISSN 1936-0851, 04/2015, Volume 9, Issue 4, pp. 3540 - 3557
Recently, a commercial albumin-bound paclitaxel (PTX) nanocarrier (Abraxane) was approved as the first new drug for pancreatic ductal adenocarcinoma in almost... 
SUPPORTED MEMBRANES | paclitaxel | PHYSICAL-PROPERTIES | synergy | mesoporous silica nanoparticle | VIVO | NAB-PACLITAXEL | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | MODEL | CYTIDINE DEAMINASE | CHEMISTRY, MULTIDISCIPLINARY | OVERCOME DRUG-RESISTANCE | co-delivery | pancreatic cancer | IN-VITRO | ratiometric | gemcitabine | BILAYERS PROTOCELLS | NANOTECHNOLOGY | Albumins - chemistry | Deoxycytidine - chemistry | Paclitaxel - pharmacology | Pancreatic Neoplasms - metabolism | Nanoparticles - chemistry | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Drug Carriers - chemistry | Pancreatic Neoplasms - drug therapy | Albumins - therapeutic use | Paclitaxel - chemistry | Deoxycytidine - therapeutic use | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Pancreatic Neoplasms - pathology | Silicon Dioxide - chemistry | Antineoplastic Agents - chemistry | Paclitaxel - therapeutic use | Drug Synergism | Albumins - pharmacology | Animals | Cell Transformation, Neoplastic | Cytidine Deaminase - metabolism | Cell Line, Tumor | Mice | Lipid Bilayers - chemistry | Porosity | Deoxycytidine - analogs & derivatives | Index Medicus | Drugs | Effectiveness | Metabolites | Biocompatibility | Lipids | Nanostructure | Tumors | Cancer
Journal Article
Pharmaceutical research, ISSN 1573-904X, 2014, Volume 32, Issue 3, pp. 1002 - 1016
Albumin nanoparticles have been explored as a promising delivery system for various therapeutic agents. One limitation of such formulations is their poor... 
Biochemistry, general | Biomedical Engineering | colloidal stability | paclitaxel | Biomedicine | Pharmacy | Medical Law | Pharmacology/Toxicology | pharmacokinetic | liposome | albumin nanoparticle | VITRO | COMPLEX MICELLES | DRUG-DELIVERY | HUMAN SERUM-ALBUMIN | CHEMISTRY, MULTIDISCIPLINARY | POLYMERIC NANOPARTICLES | FORMULATIONS | BOUND PACLITAXEL | PHARMACOLOGY & PHARMACY | POLYETHYLENE-GLYCOL | IN-VIVO EVALUATION | BLOCK-COPOLYMER | Albumins - chemistry | Injections, Intravenous | Paclitaxel - pharmacology | Albumin-Bound Paclitaxel | Humans | Half-Life | Male | Melanoma, Experimental - metabolism | Polyethylene Glycols - chemistry | Paclitaxel - pharmacokinetics | Breast Neoplasms - metabolism | Nanoparticles | Tissue Distribution | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Lipids - chemistry | G2 Phase Cell Cycle Checkpoints - drug effects | MCF-7 Cells | Female | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Nanomedicine | Cell Survival - drug effects | Drug Stability | Solubility | Melanoma, Experimental - pathology | Antineoplastic Agents, Phytogenic - chemistry | Technology, Pharmaceutical - methods | Chemistry, Pharmaceutical | Particle Size | Animals | Breast Neoplasms - pathology | Mice | Mice, Inbred BALB C | Liposomes | Antineoplastic Agents, Phytogenic - pharmacology | Thin films | Chemotherapy | Analysis | Paclitaxel | Albumin | Drugstores | Dielectric films | Chromatography | Cancer | Proteins | Drug delivery systems | Pharmaceutical sciences | Tumors
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 12/2012, Volume 6, pp. 371 - 384
The taxanes (paclitaxel and docetaxel) represent an important class of antineoplastic agents that interfere with microtubule function leading to altered... 
Taxane analogs | New antimicrotubule agents | Taxane(s) | Novel taxanes | New taxane formulations | CHEMISTRY, MEDICINAL | GYNECOLOGIC-ONCOLOGY-GROUP | POLYMERIC MICELLAR PACLITAXEL | PRIMARY PERITONEAL CANCER | new antimicrotubule agents | ADVANCED PANCREATIC-CANCER | CELL LUNG-CANCER | PHASE-III TRIAL | taxane analogs | new taxane formulations | IXABEPILONE PLUS CAPECITABINE | taxane(s) | ALBUMIN-BOUND PACLITAXEL | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | novel taxanes | DOCOSAHEXAENOIC ACID-PACLITAXEL | United States | Humans | Paclitaxel - adverse effects | Antineoplastic Agents - therapeutic use | Drug Approval | Antineoplastic Agents - administration & dosage | Paclitaxel - therapeutic use | Neoplasms - drug therapy | Taxoids - administration & dosage | Taxoids - therapeutic use | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents - adverse effects | Drug Design | Antineoplastic Agents, Phytogenic - therapeutic use | Neoplasms - pathology | Paclitaxel - administration & dosage | Taxoids - adverse effects | United States Food and Drug Administration | Antineoplastic Agents, Phytogenic - adverse effects | Antimitotic agents | Drugs | Care and treatment | Patient outcomes | Analysis | Product/Service Evaluations | Research | Antineoplastic agents | Cancer | Regulatory agencies | Toxicity | Mitosis | Lung cancer | Bladder | Yew | Taxane | Allergic reactions | Neuropathy | Drug resistance | Analogs | Paclitaxel | Needles | Myelosuppression | Gastric cancer | Taxotere | Formulations | Solvents | Evergreen trees | Squamous cell carcinoma | Sarcoma | Taxol | Hypersensitivity | Breast cancer | Pharmacology | FDA approval | Esophagus | Polyoxyethylene sorbitan monooleate | Organic chemistry | Chemotherapy | Dilution | Side effects | Cell death | Reagents | Head and neck cancer | Solid tumors | Taxanes | Prostate cancer | Epothilones | Prostate
Journal Article
Circulation, ISSN 0009-7322, 09/2017, Volume 136, Issue 12, pp. 1102 - 1113
Journal Article